What is the rationale for T-cell therapies in the treatment of smoldering MM?

During the International Myeloma Society 5th Immune Effector Cell Workshop, the Multiple Myeloma Hub was pleased to speak to Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US. We asked, What is the rationale for T-cell therapies in the treatment of smoldering MM?

In this interview, Irene Ghobrial discusses the rationale for the use of immunotherapies in smoldering multiple myeloma (MM). She highlights the increased likelihood of T-cell fitness and reduced tumor burden in earlier stages of disease; which make T-cell therapies likely to be more effective in this setting than in relapsed and refractory disease. Ghobrial concludes with a look to the future implications of earlier treatment for MM on the patient, and potentially curative options.